Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

Azacitidine Tablets Approved for AML Following Chemotherapy

The FDA approved azacitidine tablets, formerly known as CC-486, for the continued treatment of adults with acute myeloid leukemia (AML) who achieved first complete...

Geriatric Assessment Identifies Risk Factors for Worse Survival in Older Adults With AML

Older patients with acute myeloid leukemia (AML) who undergo post-remission therapy may be at risk of poor survival if they present with impaired physical...
How I Treat In Brief

How I Treat in Brief: Acute Myeloid Leukemia in the Era of New Drugs

Courtney D. DiNardo, MD, and Andrew H. Wei, MD, review recently approved therapies for acute myeloid leukemia and the treatment challenges they present. This material...
On location

Decitabine Plus Venetoclax Outperforms Intensive Chemotherapy Across Risk Groups

For older and unfit patients with acute myeloid leukemia (AML), venetoclax plus hypomethylating agents (HMAs) have been established as a standard of care and...

Indication Expanded for Gemtuzumab Ozogamicin

The FDA has extended the indication of gemtuzumab ozogamicin to include pediatric patients aged 1 month or older with newly diagnosed CD33-positive acute myeloid...
On location

A New CAR T-Cell Target for T-Cell Acute Lymphocytic Leukemia?

The anti-CD7 chimeric antigen receptor (CAR) T-cell therapy TruUCAR GC027 demonstrated promising efficacy in treating adults with relapsed or refractory T-cell acute lymphoblastic leukemia...
On location

Adding Venetoclax to Azacitidine Improves Response and Survival Rates in Treatment-Naïve AML

A combination of the hypomethylating agent azacitidine and the small-molecule BCL2 inhibitor venetoclax was associated with a 34% reduction in the risk of death,...

Improving Access to Leukemia Treatment in Brazil

With more than 200 million people, Brazil has the largest population of any South American country and is currently the seventh most populous country...
On location

Evaluating MBG453 Plus Decitabine or Azacitidine in High-Risk MDS and AML

The anti-TIM-3 checkpoint inhibitor MBG453, when added to decitabine or azacitidine, was associated with antileukemic activity and durable response rates in patients with higher-risk...

FDA Grants Orphan Drug Designation to MT-401 for AML

The FDA has granted orphan drug designation to MT-401, an allogeneic T-cell therapy for the treatment of acute myeloid leukemia (AML). MT-401, from Marker Therapeutics,...

Current Issue

September 2020 Volume 6, Issue 11

This issue features a look at the evolution of preprint platforms, an analysis of the economic and health consequences of the COVID-19 pandemic, and more.

Block title